JPWO2021183839A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183839A5 JPWO2021183839A5 JP2022555069A JP2022555069A JPWO2021183839A5 JP WO2021183839 A5 JPWO2021183839 A5 JP WO2021183839A5 JP 2022555069 A JP2022555069 A JP 2022555069A JP 2022555069 A JP2022555069 A JP 2022555069A JP WO2021183839 A5 JPWO2021183839 A5 JP WO2021183839A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 238000002659 cell therapy Methods 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988892P | 2020-03-12 | 2020-03-12 | |
| US62/988,892 | 2020-03-12 | ||
| PCT/US2021/022029 WO2021183839A2 (en) | 2020-03-12 | 2021-03-12 | Novel anti-lilrb4 antibodies and derivative products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517252A JP2023517252A (ja) | 2023-04-24 |
| JPWO2021183839A5 true JPWO2021183839A5 (ko) | 2024-03-18 |
Family
ID=77670974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555069A Pending JP2023517252A (ja) | 2020-03-12 | 2021-03-12 | 新規抗ｌｉｌｒｂ４抗体および派生産物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230340114A1 (ko) |
| EP (1) | EP4118120A4 (ko) |
| JP (1) | JP2023517252A (ko) |
| KR (1) | KR20220152316A (ko) |
| CN (1) | CN115551894A (ko) |
| AU (1) | AU2021236302A1 (ko) |
| BR (1) | BR112022018088A2 (ko) |
| CA (1) | CA3175140A1 (ko) |
| WO (1) | WO2021183839A2 (ko) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2023159152A2 (en) * | 2022-02-17 | 2023-08-24 | Immune-Onc Therapeutics, Inc. | Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor |
| TW202346337A (zh) | 2022-03-29 | 2023-12-01 | 美商恩格姆生物製藥公司 | Ilt3及cd3結合劑以及其使用方法 |
| WO2023209716A1 (en) * | 2022-04-25 | 2023-11-02 | Biond Biologics Ltd. | Anti-ilt3 antibodies and use thereof |
| WO2023235699A1 (en) * | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
| WO2023236891A1 (en) * | 2022-06-06 | 2023-12-14 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-lilrb4 antibodies and uses thereof |
| CN114716554B (zh) * | 2022-06-08 | 2022-08-26 | 尚健单抗（北京）生物技术有限公司 | 抗原结合蛋白及其应用 |
| CN115925942A (zh) * | 2022-06-08 | 2023-04-07 | 北京科诺信诚科技有限公司 | 靶向人lilrb4的纳米抗体及其应用 |
| CN117362433A (zh) * | 2022-06-30 | 2024-01-09 | 杭州尚健生物技术有限公司 | 分离的抗原结合蛋白及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2655903A1 (en) * | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| PL3216803T3 (pl) * | 2008-06-25 | 2020-10-19 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące vegf |
| US9696312B2 (en) * | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
| KR102129107B1 (ko) * | 2015-03-06 | 2020-07-02 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도 |
| EP3538141A4 (en) * | 2016-11-10 | 2020-07-15 | Merck Sharp & Dohme Corp. | ILT3 LIGAND |
| US11267886B2 (en) * | 2017-02-09 | 2022-03-08 | Bluefin Biomedicine, Inc. | Anti-ILT3 antibodies and antibody drug conjugates |
| JP7383605B2 (ja) * | 2017-06-25 | 2023-11-20 | システィミューン， インク． | 抗ｐｄ－ｌ１抗体とその作製及び使用方法 |
| AU2019339469A1 (en) * | 2018-09-13 | 2021-03-11 | Immune-Onc Therapeutics, Inc. | Novel LILRB4 antibodies and uses thereof |
-
2021
- 2021-03-12 CN CN202180034809.4A patent/CN115551894A/zh active Pending
- 2021-03-12 CA CA3175140A patent/CA3175140A1/en active Pending
- 2021-03-12 WO PCT/US2021/022029 patent/WO2021183839A2/en unknown
- 2021-03-12 EP EP21767325.0A patent/EP4118120A4/en active Pending
- 2021-03-12 KR KR1020227035314A patent/KR20220152316A/ko active Search and Examination
- 2021-03-12 AU AU2021236302A patent/AU2021236302A1/en active Pending
- 2021-03-12 BR BR112022018088A patent/BR112022018088A2/pt unknown
- 2021-03-12 JP JP2022555069A patent/JP2023517252A/ja active Pending
- 2021-03-12 US US17/905,943 patent/US20230340114A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2022022420A5 (ko) | ||
| WO2019062832A1 (zh) | Tigit抗体、其抗原结合片段及医药用途 | |
| CN111944050A (zh) | 一种抗b7-h3抗体及其应用 | |
| WO2022045247A1 (ja) | 抗切断型変異ｃａｌｒ－ｃｄ３二重特異性抗体及び医薬組成物 | |
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| CN112585165A (zh) | 优化的抗tl1a抗体 | |
| JP2013517464A (ja) | 皮膚ｔ細胞リンパ腫の診断及び処置のための方法 | |
| WO2016171242A1 (ja) | Ｅｐｈａ２の検出 | |
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| JPWO2021183839A5 (ko) | ||
| CA3184008A1 (en) | Anti-cldn18.2 antibodies and diagnostic uses thereof | |
| WO2023088221A1 (en) | Combination therapy of claudin 18.2 antagonist and pd-1/pd-l1 axis inhibitor | |
| CN112243443A (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| JP2024020436A (ja) | Ｈｅｒ２標的化剤 | |
| CN110461874A (zh) | 抗gitr抗体、其抗原结合片段及其医药用途 | |
| CN112851807B (zh) | 抗cd123抗体及其应用 | |
| CN114761042A (zh) | Il-38特异性抗体 | |
| RU2770003C1 (ru) | Моноклональное антитело к С-концевому фрагменту антимюллерова гормона | |
| CN117285627B (zh) | 抗ccr8抗体及其用途 | |
| WO2024131846A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| WO2023030258A1 (en) | Anti-4-1bb nanobodies | |
| CN118027199A (zh) | Cd138的抗体及其应用 | |
| WO2024129897A2 (en) | Anti-cd3 antibodies and bispecific antibodies | |
| CN115947845A (zh) | 一种具有cd47结合活性的单克隆抗体及其应用 |